Publication:
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Simple item page
dc.contributor.authorMazagatos, Clara
dc.contributor.authorMendioroz, Jacobo
dc.contributor.authorRumayor-Zarzuelo, Mercedes Belén
dc.contributor.authorGallardo García, Virtudes
dc.contributor.authorÁlvarez Río, Virginia
dc.contributor.authorCebollada Gracia, Ana Delia
dc.contributor.authorBatalla Rebollo, Noa
dc.contributor.authorBarranco Boada, María Isabel
dc.contributor.authorPérez-Martínez, Olaia
dc.contributor.authorLameiras Azevedo, Ana Sofía
dc.contributor.authorLópez González-Coviella, Nieves
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorFernández Ibáñez, Ana
dc.contributor.authorGiménez Duran, Jaume
dc.contributor.authorRamírez Córcoles, Cristina
dc.contributor.authorRamos Marín, Violeta
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorSARI Sentinel Surveillance RSV Study Group
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2024-06-26T11:23:19Z
dc.date.available2024-06-26T11:23:19Z
dc.date.issued2024-05
dc.description.abstractBackground: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipDuring the implementation of sentinel SARI surveillance in Spain, some Autonomous Communities received funding from ECDC (Establishing Severe Acute Respiratory Infections [SARI] surveillance and performing hospital-based COVID-19 transmission studies, ECDC.11236.2021). Researchers at the National Centre of Epidemiology (Institute of Heath Carlos III) received funding from ECDC through the project ‘ECDC Hospital network for Vaccine Effectiveness, Burden and Impact Studies and for Surveillance of Severe Acute Respiratory Infections’ Framework Contract no. ECDC/2021/016, within the ‘Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza’ platform.es_ES
dc.format.number5es_ES
dc.format.pagee13294es_ES
dc.format.volume18es_ES
dc.identifier.citationInfluenza Other Respir Viruses. 2024 May;18(5):e13294.es_ES
dc.identifier.doi10.1111/irv.13294es_ES
dc.identifier.e-issn1750-2659es_ES
dc.identifier.journalInfluenza and other respiratory viruseses_ES
dc.identifier.pubmedID38716791es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19872
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC.11236.2021es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/016es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/irv.13294es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSARIes_ES
dc.subjectBurdenes_ES
dc.subjectImpactes_ES
dc.subjectRespiratory infectionses_ES
dc.subjectRespiratory syncitial viruses_ES
dc.subjectSurveillancees_ES
dc.subject.meshRespiratory Syncytial Virus Infectionses_ES
dc.subject.meshHospitalizationes_ES
dc.subject.meshAntiviral Agentses_ES
dc.subject.meshHumanses_ES
dc.subject.meshSpaines_ES
dc.subject.meshInfantes_ES
dc.subject.meshIncidencees_ES
dc.subject.meshFemalees_ES
dc.subject.meshMalees_ES
dc.subject.meshRespiratory Syncytial Virus, Humanes_ES
dc.subject.meshSentinel Surveillancees_ES
dc.subject.meshInfant, Newbornes_ES
dc.subject.meshAntibodies, Monoclonal, Humanizedes_ES
dc.titleEstimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spaines_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublicatione77e1f2d-b4e2-4ba5-a853-c2795850dcae
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication.latestForDiscoverye177bf8c-3734-480b-a2ae-4ae67491776c
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
EstimatedImpactNirsevimabVRS_2024.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Download
Thumbnail Image
Name:
Supplement_EstimatedImpactNirsevimabVRS_2024.pdf
Size:
984.56 KB
Format:
Adobe Portable Document Format
Description:
supplementary material
Download

Collections

Centro Nacional de Epidemiología (CNE)
IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)